Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965987 | 0.91 | CALCA (0.49) | CALCAKDM4ESMN1; SMN2 | |
| SCHEMBL967390 | 0.87 | CALCA (0.42) | CALCAKDM4ESMN1; SMN2 | |
| SCHEMBL965779 | 0.86 | CALCA (0.48) | CALCAKDM4ESMN1; SMN2 | |
| SCHEMBL967789 | 0.86 | CALCA (0.42) | CALCAKDM4ESMN1; SMN2 | |
| SCHEMBL967706 | 0.84 | CALCA (0.41) | CALCAKDM4ESMN1; SMN2 | |
| SCHEMBL968042 | 0.84 | CALCA (0.50) | CALCAKDM4ESMN1; SMN2 | |
| SCHEMBL966987 | 0.84 | CALCA (0.50) | CALCAKDM4ESMN1; SMN2 | |
| SCHEMBL965627 | 0.84 | CALCA (0.51) | CALCAKDM4ESMN1; SMN2 | |
| SCHEMBL967383 | 0.83 | CALCA (0.42) | CALCAKDM4ESMN1; SMN2 | |
| SCHEMBL966272 | 0.82 | CALCA (0.47) | CALCAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | claimed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | PCNA, SAMHD1, NTPCR | CALCA 4461/4885KDM4E 2029/4885SMN1; SMN2 4318/4885 |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | PCNA, SAMHD1, NTPCR | CALCA 4461/4885KDM4E 2029/4885SMN1; SMN2 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.